###begin article-title 0
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 392 398 <span type="species:ncbi:9606">humans</span>
Mutations in the ataxia-telangiectasia mutated (ATM) and checkpoint kinase 2 (CHEK2) genes and amplification of the v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene have been suggested to have an important role in breast cancer aetiology. However, whether common variation in these genes has a role in the development of breast cancer or breast cancer survival in humans is still not clear.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 55 58 55 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 446 452 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 482 488 482 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 581 582 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 582 584 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
We performed a comprehensive haplotype analysis of the ATM, CHEK2 and ERBB2 genes in a Swedish population-based study, which included 1,579 breast cancer cases and 1,516 controls. We followed the cases for 8.5 years, on average, and retrieved information on the date and cause of death during that period from the nationwide Swedish causes of death registry. We selected seven haplotype-tagging SNPs (tagSNPs) in the ATM gene, six tagSNPs in the CHEK2 gene and seven tagSNPs in the ERBB2 gene that predicted both haplotypic and single locus variations in the respective genes with R2 values >/= 0.8. These tagSNPs were genotyped in the complete set of cases and controls. We computed expected haplotype dosages of the tagSNP haplotypes and included the dosages as explanatory variables in Cox proportional hazards or logistic regression models.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 61 64 61 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
We found no association between any genetic variation in the ATM, CHEK2 or ERBB2 genes and breast cancer survival or the risk of developing tumours with certain characteristics.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 456 461 <span type="species:ncbi:9606">human</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
Twin and family studies consistently indicate that the risk of breast cancer is influenced, in part, by hereditary factors, but high-risk mutations seem to account for only 1-2% of all breast cancer cases in the general population [1]. A polygenic model has been proposed to account for the residual familial risk [2], which anticipates small effects of several low-penetrance genetic risk variants in combination with environmental influence. Although no human data exist for the affect of germ-line polymorphisms on tumour outcome, there is strong evidence that strain background is a significant determinant of the clinical behaviour of experimental mammary carcinomas in mice [3-5]. We thus set out to study the role of common variation in key breast cancer candidate genes in relation to breast cancer aetiology, survival and tumour characteristics.
###end p 11
###begin p 12
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 470 474 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 717 723 717 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 820 829 820 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1100delC </italic>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 954 960 954 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 963 969 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1063 1065 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1066 1068 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1195 1197 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1207 1213 1207 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 1347 1349 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1350 1352 1350 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
The ataxia-telangiectasia mutated (ATM; MIM 607585), checkpoint kinase 2 (CHEK2; MIM 604373) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2; also named HER2; MIM 164870) genes have been suggested to have an important role in breast cancer aetiology. The ATM protein is activated in response to ionizing radiation and triggers phosphorylation of CHEK2 and other proteins that promote cell cycle arrest and activation of DNA repair [6-12]. The ATM gene is mutated in the rare autosomal recessive disorder ataxia-telangiectasia (A-T) and the risk of breast cancer has been found to be increased in relatives of A-T patients [13,14], in addition to A-T heterozygotes [15,16]. Mutations in the CHEK2 gene have been found in patients with Li-Fraumeni syndrome [17] and one such mutation - the rare 1100delC gene mutation - has been found to increase breast cancer susceptibility at the population level [18] and in families without BRCA1 or BRCA2 gene mutations [19,20]. ERBB2 is a transmembrane glycoprotein, with tyrosine kinase activity [21-25], that has a major role in signal transduction, thereby affecting cell proliferation, differentiation, motility and survival [26-28]. The ERBB2 gene is amplified and/or overexpressed in approximately 30% of breast tumours, a phenomenon that is associated with a poor prognosis [29-31].
###end p 12
###begin p 13
###xml 35 46 35 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM, CHEK2 </italic>
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 226 229 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 231 237 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 680 686 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 804 808 804 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 812 818 812 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
Until now, common variation in the ATM, CHEK2 and ERBB2 genes has mainly been studied in relation to the overall risk of breast cancer, but the results have been inconclusive. It is worthwhile studying common variation in the ATM, CHEK2 and ERBB2 genes in relation to breast cancer progression because defects in the genes could increase the risk of developing tumours with an unfavourable prognosis through their role in the regulation of cell cycle checkpoints and amplification. Variation in the genes could also affect cancer survival through increased radiosensitivity [32-34]. One group found a relationship between poor breast cancer prognosis and common haplotypes in the ERBB2 gene [35], but to our knowledge, nothing has been reported regarding the association between common haplotypes in the ATM and CHEK2 genes and breast cancer survival or tumour characteristics. Hence, many questions regarding the role of these genes in breast cancer survival and the progression of breast cancers are unanswered.
###end p 13
###begin p 14
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 391 397 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 581 587 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
We performed a haplotype analysis of the ATM, CHEK2 and ERBB2 genes by genotyping a dense set of markers in each gene in 92 randomly selected controls, thus acquiring a comprehensive coverage of the common variation in each entire gene. We genotyped selected haplotype-tagging SNPs (tagSNPs) in a well-defined, Swedish population. We then assessed the association of the tagSNPs in the ATM, CHEK2 and ERBB2 genes and their haplotypes with breast cancer survival and the risk of tumour-characteristic-defined breast cancer. We also studied the tagSNPs and haplotypes in the ATM and ERBB2 genes, in addition to two mis-sense mutations in the ATM gene (2572 T-->C and 4258 C-->T), in relation to the overall risk of breast cancer.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Study population
###end title 16
###begin p 17
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 41 46 <span type="species:ncbi:9606">women</span>
###xml 484 489 <span type="species:ncbi:9606">women</span>
The study base included all Swedish-born women between 50 and 74 years of age who were resident in Sweden between October 1993 and March 1995. During that period, we identified all breast cancer cases at diagnosis through the six regional cancer registries in Sweden, which provide virtually complete data on incident cancers in Sweden [36]. We randomly selected controls, who matched the cases in 5-year age strata, from the Swedish registry of the total population. Of the eligible women, 3,345 (84%) breast cancer cases and 3,454 (82%) controls participated in this initial questionnaire-based study, providing detailed information on their use of menopausal hormone therapy, their reproductive history and other lifestyle factors. Results from the study have been published [37-41].
###end p 17
###begin p 18
###xml 201 209 201 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 138 150 <span type="species:ncbi:9606">participants</span>
###xml 558 563 <span type="species:ncbi:9606">women</span>
From this initial study, we randomly selected 1,500 breast cancer cases and 1,500 age-frequency-matched controls among the postmenopausal participants without any previous malignancy (except carcinoma in situ of the cervix or nonmelanoma skin cancer). With the intention of increasing the statistical power in subgroup analyses, we further selected all of the remaining breast cancer cases and controls who had used menopausal hormones (oestrogen alone or any combination of oestrogen and progestin) for at least 4 years (191 cases and 108 controls) and all women with self-reported diabetes mellitus (110 cases and 104 controls). Additionally, 345 controls, who were included in both the initial breast cancer study and an endometrial cancer study with the same study base and inclusion criteria, were added to the control group. In total, we selected 1,801 breast cancer cases and 2,057 controls.
###end p 18
###begin p 19
###xml 37 49 <span type="species:ncbi:9606">participants</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 111 116 <span type="species:ncbi:9606">women</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
After informed consent was obtained, participants donated whole blood. For deceased breast cancer patients and women who declined to donate blood but consented to the use of tissue samples, we collected archived paraffin-embedded, noncancerous tissue samples. We acquired 70% of the requested tissue samples; the main reason for nonparticipation was unwillingness or a lack of time at the respective pathology department to provide the tissue blocks. In total, we obtained 1,321 blood samples and 275 archived tissue samples from the breast cancer patients and 1,524 blood samples from the controls. The mean time from diagnosis to the arrival of the blood and tissue samples at our department was 5 years. Reasons for nonparticipation included a lack of interest in research, a negative attitude towards genetic research, old age and severe disease or death. Population-based participation rates (taking into account the proportion of individuals who did not participate in the questionnaire-based study) for the breast cancer cases and controls were 75% and 61%, respectively.
###end p 19
###begin p 20
This study was approved by the Institutional Review Boards in Sweden and the National University of Singapore.
###end p 20
###begin title 21
DNA isolation
###end title 21
###begin p 22
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
The Swegene laboratories in Malmo (Sweden) extracted DNA from 4 ml of whole blood using the QIAamp DNA Blood Maxi Kit (Qiagen, Solna, Sweden) according to the manufacturer's instructions. From nonmalignant cells in paraffin-embedded tissue, we extracted DNA using a standard phenol/chloroform/isoamyl alcohol protocol [42]. We successfully isolated DNA from 1,318 blood samples and 272 tissue samples from the breast cancer patients and 1,518 blood samples from the controls.
###end p 22
###begin title 23
SNP markers and genotyping
###end title 23
###begin p 24
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 255 258 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 894 897 894 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 899 905 899 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 908 914 908 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
The ATM gene covers 146.3 kb of genomic sequence on chromosome 11, the CHEK2 gene spans 54.1 kb on chromosome 22 and the ERBB2 gene covers 33.7 kb on chromosome 17 (build 125 in the dbSNP (Single Nucleotide Polymorphism database). We selected SNPs in the ATM, CHEK2 and ERBB2 genes and their 10 kb flanking sequences from dbSNP (build 124) and Celera databases aiming for an initial marker density of at least one SNP per 5 kb. SNPs were genotyped using the Sequenom primer extension-based assay (San Diego, CA, USA) and the BeadArray system (Illumina, San Diego, CA, USA) according to the manufacturers' instructions. All genotyping results were generated and checked by laboratory staff unaware of case-control status. Only SNPs for which >85% of the samples gave a genotype call were analysed further. As a quality control, we genotyped 200 randomly selected SNPs (not including SNPs in the ATM, CHEK2 or ERBB2 genes) in the 92 control samples using both the Sequenom system and the BeadArray system. The genotype concordance was >99.5%, suggesting high genotyping accuracy.
###end p 24
###begin title 25
Characterization of linkage disequilibrium and haplotype-tagging SNP selection
###end title 25
###begin p 26
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 370 372 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 655 656 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 656 658 652 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 674 676 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 864 866 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 867 869 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1041 1042 1035 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1042 1044 1036 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1245 1247 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1248 1250 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
We produced linkage disequilibrium (LD) plots of the D' values for ATM and ERBB2 genes (supplementary Figures 1 and 2, respectively) using the Haploview program [43]. We reconstructed haplotypes for all three genes using the partition-ligation-expectation-maximization (PLEM) algorithm [44] implemented in the tagSNPs program [45] and selected tagSNPs according to the R2 coefficient, which quantifies how well the tagSNP haplotypes predict the SNPs or the number of copies of haplotypes that an individual carries. We chose tagSNPs so that common SNP genotypes (minor allele frequency >/=0.03) and common haplotypes (frequency >/=0.03) were predicted by R2 values >/= 0.8 [46]. To evaluate the performance of our tagSNPs in capturing unobserved SNPs within the genes and to assess whether a denser set of markers was needed, we performed a SNP-dropping analysis [47,48]. In brief, each of the genotyped SNPs was dropped in turn and tagSNPs were selected from the remaining SNPs so that their haplotypes predicted the remaining SNPs with an R2 value of 0.85. We then estimated how well the tagSNP haplotypes of the remaining SNPs predicted the dropped SNP, an evaluation that can provide an unbiased and accurate estimate of tagSNP performance [47,48].
###end p 26
###begin title 27
Tumour characteristics and follow-up
###end title 27
###begin p 28
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1203 1205 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
We retrieved information on the date and cause of death (until 31 December 2003) from the Swedish causes of death registry and the date of emigration from the Swedish national population registry. Information from the causes of death registry in Sweden has been found to be of high quality [49]. The follow-up time began at the date of diagnosis and ended on 31 December 2003 or at the date of death or emigration, whichever came first. We collected information on tumour characteristics, such as tumour size, lymph-node involvement, grade (tumour differentiation), histological type and date of the first distant metastasis, from medical records. We obtained information on the oestrogen and progesterone receptor content and S-phase fraction (i.e. the proportion of tumour cells in the DNA synthesis phase of the cell cycle) of the tumours from seven laboratories around Sweden that routinely perform these tumour measurements for the whole country. At the time of the study, all seven laboratories used an enzyme immunoassay (Abbott Laboratories, Solna, Sweden) on cytosol samples for analysing the oestrogen and progesterone receptor content. This method was oestrogen receptor type alpha specific [50]. The laboratories reported either quantitative measurements (fmol receptor per mug DNA or mg protein and the percentage of cells in S-phase) or categorical measurements (strongly positive, positive, weakly positive or negative for receptor status and high, intermediate or low S-phase fraction). A rather high proportion of this information was missing, which was owing to the fact that these measurements were not routinely performed in the mid-1990s. We classified the tumour characteristics as follows:
###end p 28
###begin p 29
1. TNM stage:
###end p 29
###begin p 30
1.a. Stage 1 - tumour size </=20 mm and no regional lymph-node metastases.
###end p 30
###begin p 31
1.b. Stage 2 - tumour size </=20 mm and lymph-node metastases, or tumour size 20-</=50 mm, or tumour size >50 mm and no lymph-node metastases.
###end p 31
###begin p 32
1.c. Stage 3 - an inflammatory breast tumour, or tumour size >50 mm and lymph-node metastases.
###end p 32
###begin p 33
1.d. Stage 4 - distant metastasis within 90 days of diagnosis.
###end p 33
###begin p 34
2. Lymph-node involvement:
###end p 34
###begin p 35
2.a. Yes - at least one metastasised lymph node.
###end p 35
###begin p 36
2.b. No - no metastasised lymph node.
###end p 36
###begin p 37
3. Grade:
###end p 37
###begin p 38
3.a. High differentiation.
###end p 38
###begin p 39
3.b. Intermediate differentiation.
###end p 39
###begin p 40
3.c. Low differentiation.
###end p 40
###begin p 41
4. Oestrogen and progesterone receptor status:
###end p 41
###begin p 42
4.a. Positive - >/=0.05 fmol/mug DNA, >/=10 fmol/mg protein or categorically strongly positive, weakly positive or positive.
###end p 42
###begin p 43
4.b. Negative - <0.05 fmol/mug DNA, <10 fmol/mg protein or categorically negative.
###end p 43
###begin p 44
5. S-phase fraction:
###end p 44
###begin p 45
5.a. High - >/=9% or categorically high.
###end p 45
###begin p 46
5.b. Low - <9% or categorically low.
###end p 46
###begin p 47
We combined TNM stage 3 and TNM stage 4 in all association analyses because of small numbers.
###end p 47
###begin title 48
Statistical analyses
###end title 48
###begin p 49
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
In assessing the association with tumour-characteristic-defined breast cancer, we stratified the cases on breast cancer subtypes and compared each group with the controls. Our testing strategy was to fit a single model and assess within each stratum of risk-factor subgroup and for different tumour characteristics, haplotype-trait associations as a global likelihood ratio test [51]. We first computed expected haplotype dosage using the tagSNPs program [45], with haplotype frequencies estimated for the breast cancer cases and controls combined, assuming Hardy-Weinberg equilibrium (HWE) of haplotypes. We then, included the haplotype dosages as explanatory variables in the regression models. To estimate the power in the risk component of the study, we used a method described by Chapman and colleagues [52], which assumes co-dominant effects at an unobserved locus. To calculate the power for log-additive effects in the survival component of the study, we used the Quanto program [53] in a similar manner to that described by Manolio and colleagues [54].
###end p 49
###begin p 50
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 489 491 489 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
We applied unconditional logistic regression models adjusted for age (in 5-year age-groups) to assess the relationship between the ATM, CHEK2 and ERBB2 tagSNP haplotypes and the overall risk of breast cancer, in addition to breast cancer subtypes. We estimated the hazard ratio of death owing to breast cancer in relation to the genes' tagSNP haplotypes using Cox proportional hazards models. The appropriateness of these approaches is supported by Stram and colleagues [45]. That is, if R2 values are high, such as here, the point and interval estimates obtained by this approach will be approximately accurate. To assess the proportional hazards assumptions of the Cox models, we examined scaled Schoenfeld residuals and found no evidence against proportionality.
###end p 50
###begin p 51
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
'Confounding' has been defined as the presence of a common cause of the exposure and outcome [55]. We believe that lifestyle and reproductive breast cancer risk factors are unlikely to cause genetic variation in the genes, but they could be intermediates in the causal pathway between the genes and both breast cancer and tumour-characteristic-defined breast cancer. For completeness, we assessed whether the tagSNPs were associated with known breast cancer risk factors (age at menarche, age at menopause, body mass index, age at first birth, parity, menopausal hormone use and diabetes mellitus) among the randomly selected controls using Kruskal-Wallis and Chi square tests. Analyses were performed using the SAS system (release 9.1; SAS Institute Inc., Cary, NC, USA).
###end p 51
###begin title 52
Results
###end title 52
###begin title 53
Study population
###end title 53
###begin p 54
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 583 585 583 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 737 739 737 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 777 779 777 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Characteristics of breast cancer cases in the parent case-control study and the current genetic association study are described in Table 1. With respect to nongenetic factors among cases and controls [56] and tumour characteristics among cases (Table 1), the current study was representative of the parent study. Breast-cancer-specific death rates among the cases in the current study reflected known prognostic information on various tumour characteristics (Table 1). Tumours with unknown hormone receptor status or S-phase fraction were smaller in both parent and current studies (P < 0.0001 for both receptor status and S-phase fraction). Missing information on tumour grade depended significantly on tumour size in the parent study (P = 0.01) but not in the current study (P = 0.15).
###end p 54
###begin p 55
###xml 89 91 89 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Cases who participated through tissue sample donation were, on average, 1.5 years older (P = 0.0003) and more likely to have been diagnosed with TNM stage 2 or more advanced cancers (P < 0.0001) compared with cases who donated a blood sample. Importantly, no significant differences in the genotype frequencies were evident between cases who participated through blood or tissue sample donation.
###end p 55
###begin title 56
Estimation of the pattern of linkage disequilibrium and coverage
###end title 56
###begin p 57
###xml 79 82 79 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 148 151 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 278 281 278 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 488 494 488 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 646 650 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 670 676 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 699 705 699 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1078 1079 1078 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
We summarize the statistics for the genotyping results and SNP coverage in the ATM, CHEK2 and ERBB2 genes in supplementary Table 1. The SNPs in the ATM, ERBB2 and CHEK2 genes that were successfully genotyped in 92 randomly selected controls are listed in supplementary Table 2 (ATM) and 3 (ERBB2), and have been previously published in Table 2 by Einarsdottir and colleagues [56] (CHEK2). In brief, our study included 51 SNPs in the ATM gene, 14 SNPs in the CHEK2 gene and 13 SNPs in the ERBB2 gene that were successfully genotyped - and were in HWE - in the 92 controls. The mean spacing between the SNPs included in our study was 2.9 kb in the ATM gene, 4.0 kb in the CHEK2 gene and 2.8 kb in the ERBB2 gene. We detected strong LD across all three genes [supplementary Figure 1, Figure 1 in Einarsdottir and colleagues [56] and supplementary figure 2, respectively]. Using the SNP dropping method [47], we found that the tagSNPs selected from the SNPs included in our study could capture nongenotyped SNPs as efficiently as the SNPs included in our study (supplementary Table 1).
###end p 57
###begin title 58
Breast cancer survival
###end title 58
###begin p 59
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 57 68 57 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM, CHEK2 </italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 632 638 632 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Table 2 summarizes the information on the tagSNPs in the ATM, CHEK2 and ERBB2 genes that we genotyped in breast cancer cases and controls. All of the tagSNPs in the CHEK2 and ERBB2 genes and two of the tagSNPs in the ATM gene were not only genotyped in breast cancer cases and controls who participated through blood sample donation, but were also genotyped in breast cancer cases who participated through tissue sample donation. None of the tagSNPs deviated significantly from HWE among the controls or showed a meaningful association with known breast cancer risk factors. Only one of the tagSNPs - TAG5 (also named I655V) in the ERBB2 gene - conferred an amino acid change in the protein product.
###end p 59
###begin p 60
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 280 282 280 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 396 398 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 643 645 643 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 798 800 798 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 863 865 863 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 876 878 876 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
We estimated the risk of death from breast cancer associated with the tagSNPs (Table 2) in the ATM, CHEK2 and ERBB2 genes or their haplotypes (Table 3). We found a decreased risk of death from breast cancer associated with each addition of the rare TAG2 allele in the CHEK2 gene (P = 0.026) and an elevated risk of death from breast cancer associated with the rare TAG6 allele in the CHEK2 gene (P = 0.03), compared with homozygotes of the common allele for each variant. The associations did not, however, withstand Bonferroni correction. Carriers of haplotype 2 in the CHEK2 gene seemed to have a decreased risk of death from breast cancer (P = 0.038) compared with haplotype 1 carriers, whereas carriers of the rare ERBB2 haplotypes seemed to have an increased risk of death from breast cancer (P = 0.009). Neither association carried over to the global test (P = 0.15 and P = 0.45, respectively).
###end p 60
###begin p 61
###xml 20 21 20 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
We noticed in Table 3 that all of the ATM haplotypes conferred a decrease in risk of death from breast cancer compared with haplotype 1. We therefore assessed the association of haplotype 1 with the risk of death from breast cancer and found a nonsignificantly elevated risk compared with noncarriers [odds ratio (OR), 1.13; 95% confidence interval (CI), 0.92-1.40].
###end p 61
###begin title 62
Tumour characteristics
###end title 62
###begin p 63
###xml 21 23 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 513 515 513 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
We calculated global P values for the association between the tagSNP haplotypes in the ATM, CHEK2 and ERBB2 genes and the risk of tumour-characteristic-defined breast cancer from logistic regression models. Cases were divided into groups according to their tumour characteristics and each group contrasted against all controls. Each logistic regression model included the common haplotypes and the combined group of rare haplotypes, with the most common haplotype used as a reference standard. None of the global P values reached significance (supplementary Table 4), which indicates that none of the individual haplotypes affected the risk of developing tumours with certain characteristics.
###end p 63
###begin p 64
###xml 17 32 17 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 1100delC </italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
We genotyped the CHEK2 1100delC gene mutation in our study population and have previously reported its effect on the overall risk of breast cancer [56]. The deletion was very rare in our study population, with a frequency of 0.7% among the cases and 0.4% among the controls. We could therefore not perform a meaningful analysis of the association between the deletion and breast cancer characteristics or survival in the current study.
###end p 64
###begin title 65
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Overall risk of breast cancer: the ATM and ERBB2 genes
###end title 65
###begin p 66
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
We found no effect of the ATM or ERBB2 tagSNPs (supplementary Table 5) or haplotypes (supplementary Table 6) on the overall risk of breast cancer, which was not altered after conditioning on the selection variables (menopausal hormone therapy and diabetes mellitus) or restricting the analyses to the randomly selected cases and controls. Stratifying the haplotype results by known breast cancer risk factors did not yield any additional compelling findings (supplementary Table 7).
###end p 66
###begin p 67
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
We genotyped two mis-sense mutations in the ATM gene in the complete sample set: 4258 C-->T (rs1800058; L1420F) and 2572 T-->C (rs1800056; F858L). Neither mutation deviated significantly from HWE in controls. They were both rare in our study population, with a minor allele frequency of 1.9% for 4258 C-->T and 1.4% for 2527 T-->C in the controls. In exploring the change in the risk of breast cancer with each addition of the rare allele compared with noncarriers (assuming co-dominance), an elevated - but not significant - risk for the 4258 C-->T (OR, 1.36; 95% CI, 0.91-2.04) was found, but no association emerged between the 2527 T-->C and the risk of breast cancer (OR, 1.05; 95% CI, 0.65-1.71).
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
###xml 30 41 30 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM, CHEK2 </italic>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 693 700 <span type="species:ncbi:9606">patient</span>
Although the gene products of ATM, CHEK2 and ERBB2 are involved in various aspects of breast cancer development and progression, our results suggest that common variation in these genes does not affect survival, tumour-characteristic-defined risk or the overall risk of breast cancer. We carefully studied these associations, both overall and in subgroups of known nongenetic breast cancer risk factors, using large population-based case-control material, and conclude that on the population level, common genetic variation in these genes is not of great importance for these outcomes. This does not preclude the possibility that more crucial - and rare - variation is influential in selected patient groups.
###end p 69
###begin p 70
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 36 48 <span type="species:ncbi:9606">participants</span>
Our study was population-based. All participants were born in Sweden between 1919 and 1944, a time at which foreign immigration to Sweden was still rare [57], which means population stratification is of limited concern in our study. To minimize exposure misclassification, we applied genotyping methods with low error rates (the Sequenom and Illumina methods have genotyping error rates of 0.5% and 0.3%, respectively), DNA samples were randomly assigned to the genotyping plates and the genotyping personnel were blinded to case-control status. Furthermore, we replicated genotype calls of 200 randomly selected SNPs for a subset of samples using a separate genotyping method with >99.5% concordance.
###end p 70
###begin p 71
The oestrogen and progesterone receptor status of tumours and S-phase fraction were assessed at seven different laboratories in Sweden, but it is doubtful that the genotype frequencies could be related to any interlaboratory differences. A large proportion of the information on receptor status, S-phase fraction and grade was missing. Assessment of receptor status and S-phase fraction was, to a large extent, dependent on the size of the tumour, but evaluation of the tumour grade was mostly dependent on the pathologist's decision. Because genotype frequencies were not related to tumour size, bias owing to the missing information on these factors seems unlikely.
###end p 71
###begin p 72
###xml 348 351 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 362 368 362 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
Survival bias could be a concern in our study because nonparticipation was related to severe disease or death. However, we obtained the majority of the tissue samples requested for deceased patients with breast cancer or breast cancer cases who had declined donation of a blood sample. The lack of tissue accessibility is unlikely to be related to ATM, ERBB2 or CHEK2 genetic variation because it depended on the inability of the respective pathology department to retrieve the samples. The genotype frequencies of the tagSNPs in the ERBB2 and CHEK2 genes did not differ between blood and tissue samples, suggesting that the survival bias was negligible. We were not able to genotype TAG1, TAG2, TAG3, TAG6 and TAG7 in the ATM gene in the tissue samples, but because the results were not different in the analyses restricted to the most severe cases among those who donated blood samples indicates that this was not a major problem in our study.
###end p 72
###begin p 73
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 328 330 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 367 370 367 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 949 952 941 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 968 974 960 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 992 998 984 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 1196 1201 1184 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 1273 1278 1261 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
The loss of power from testing SNPs indirectly is thought to be related to the R2 measure [46,58], but exceptions to these assumptions have been reported [59]. We assessed the capability of the tagSNPs to convey an association signal from unobserved, in addition to observed, SNPs. We captured the unobserved SNPs with average R2 values of 0.92, 0.72 and 0.93 in the ATM, ERBB2 and CHEK2, genes, respectively, and thus suffered minimal loss of power owing to indirect testing. We performed standard power calculations assuming alpha = 0.05, thus giving an indication regarding the general power of our study. We acknowledge, however, that the power is reduced in the subgroup analyses (an effect cannot be excluded in the smallest groups) and at lower alpha-levels (required when multiple tests are carried out). For the ability of haplotypes to predict the allele count at a causal locus with a minor allele frequency of 0.20, we had 89% power for ATM, 73% power for ERBB2 and 87% power for CHEK2 to detect an odds ratio of 1.3 in the risk component of the study. To detect a hazard ratio of 1.4, with an alpha-level of 0.05, in the survival component of the study, we had 50% power for TAG1 in CHEK2, which had a minor allele frequency of 0.13, and 76% power for TAG5 in CHEK2, which had a minor allele frequency of 0.38.
###end p 73
###begin p 74
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
Our data did not support an association between common variation in the ATM, CHEK2 and ERBB2 genes and breast cancer survival or the risk of developing tumours of different characteristics. Hence, we did not confirm the finding of Han and colleagues who found that an ERBB2 haplotype composed of two nonsynonymous tagSNPs - I655V and P1170A - increased the risk of breast cancer death or recurrence [35]. We included the I655V as a tagSNP in our study and genotyped the P1170A in the 92 controls. We found no effect of the I655V on breast cancer survival or tumour characteristics defined breast cancer.
###end p 74
###begin p 75
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 362 371 362 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1100delC </italic>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
To our knowledge, no study has investigated ATM or CHEK2 common haplotypes in relation to breast cancer survival or tumour characteristics, although one study explored the effect of three common polymorphisms in ATM and two polymorphisms in CHEK2 on breast cancer survival [60]. This study found no association, which is in agreement with our findings. The rare 1100delC mutation in the CHEK2 gene has been associated with breast tumours of high grade [61], in addition to steroid receptor-positive breast tumours, but not with overall survival [62]. The mutation was too rare in our study population to be investigated in relation to breast cancer survival or tumour characteristics.
###end p 75
###begin p 76
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 255 261 255 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 694 700 694 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1071 1077 1071 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 1195 1201 1195 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1235 1237 1235 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
We previously found no association between common variation in the CHEK2 gene and overall risk of breast cancer [56], which was in agreement with earlier findings [63]. In this study, we, correspondingly, found no effect of common variation in the ATM or ERBB2 genes on the risk of breast cancer, even when the results were stratified by known breast cancer risk factors. One study of the ATM gene [64] and two studies of the ERBB2 gene [35,65] are in agreement with our findings. Tamimi and colleagues found no association between the haplotypes of five Hapmap tagSNPs (one of which was TAG7 in our study) in the ATM gene and the risk of breast cancer [64]. Benusiglio and colleagues explored ERBB2 haplotypes composed of five tagSNPs [three of which were TAG2, TAG3 and TAG5 in our study] - including the nonsynonymous I655V and P1170A - in relation to the risk of breast cancer [65], whereas Han and colleagues solely studied the I655V and P1170A as tagSNPs [35]. Neither study found any effect of the haplotypes on the risk of breast cancer. Common haplotypes in the ERBB2 gene thus do not seem to affect the risk of breast cancer, although results regarding the I655V common variant in the ERBB2 gene have been conflicting [35,65-67]. We found no association of the I655V with the risk of breast cancer.
###end p 76
###begin p 77
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
Three groups have found an association between specific ATM common haplotypes and the risk of breast cancer [68-70]. Lee and colleagues [70] and Koren and colleagues [68] reconstructed haplotypes in the ATM gene from five and eight randomly selected common SNPs, respectively, whereas Angele and colleagues [69] included 11 common SNPs in the ATM gene for their haplotype estimation that had been either previously reported in the literature or detected by sequencing. SNP selection overlapped somewhat between the three studies, but none of them reported the probability of their SNPs being able to predict underlying variation in the gene. Furthermore, findings from two of the three groups [68,69] were derived from small sample sizes.
###end p 77
###begin p 78
###xml 47 51 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 102 104 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 105 107 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 108 110 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 221 223 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 224 226 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 250 252 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 253 255 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 256 258 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 373 377 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 653 655 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 772 774 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 775 777 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 778 780 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 842 844 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
The 4258 C-->T and 2527 T-->C mutations in the ATM gene have been detected in breast cancer patients [69,71-73], but to the best of our knowledge, these mutations have not been reported in A-T patients. In line with two [69,72] out of three reports [69,71,72], we found an elevated - but not significant - risk of breast cancer in carriers of the rare 4258 T allele in the ATM gene. We did not, however, find such an association in carriers of the 2527 C allele. One study found a twofold increase in the risk of breast cancer that was related to the 2527 T-->C mutation in a population from USA, but did not confirm the finding in a Polish population [73]. Three other groups did not detect any significant effect of the 2527 T-->C mutation on the risk of breast cancer [69,71,72], although one of the groups found elevated point estimates [72].
###end p 78
###begin p 79
###xml 146 148 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 224 228 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 321 323 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 425 427 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 513 517 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 657 659 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 660 662 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 663 665 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 717 721 713 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 851 853 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 1006 1008 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 1083 1087 1079 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 1215 1217 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 1218 1220 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1221 1223 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 1224 1226 1220 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
Although the 4258 C-->T and 2527 T-->C mis-sense variants do not seem to target residues known to be crucial for the function of the ATM protein [72], an increasing amount of evidence suggests that mis-sense variants in the ATM gene cause chromosomal instability and abolish the radiation-induced kinase activity of ATM [74]. Mutant ATM protein also seems to interfere with normal ATM function in a dominant-negative manner [74]. Previous mutation screening studies have indicated that mis-sense mutations in the ATM gene - rather than protein-truncating mutations - are over-represented in patients with breast cancer compared with the general population [72,75-79]. A recent publication refuted this and found that ATM gene mutations that cause A-T - that is, truncating, splicing and mis-sense mutations - are breast cancer susceptibility alleles [80]. They found a greater than twofold increase in the risk of breast cancer related to a combination of 12 mutations, including six truncating mutations [80]. Thus, controversy remains both regarding which type of mutations in the ATM gene are involved in breast cancer aetiology and which mutations actually drive the association with the risk of breast cancer [69-73,81-85].
###end p 79
###begin title 80
Conclusion
###end title 80
###begin p 81
###xml 133 136 133 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Our study had a sound epidemiological design and a comprehensive coverage of SNPs. The results indicate that common variation in the ATM, CHEK2 or ERBB2 genes does not have a role in breast cancer aetiology or progression.
###end p 81
###begin title 82
Abbreviations
###end title 82
###begin p 83
A-T = ataxia-telangiectasia; ATM = ataxia-telangiectasia mutated; CHEK2 = checkpoint kinase 2; CI = confidence interval; dbSNP = Single Nucleotide Polymorphism database; ERBB2 = v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; HWE = Hardy-Weinberg equilibrium; kb = kilobase; LD = linkage disequilibrium; OR = odds ratio; SNP = single nucleotide polymorphism; tagSNP = haplotype-tagging SNP.
###end p 83
###begin title 84
Competing interests
###end title 84
###begin p 85
The authors declare that they have no competing interests.
###end p 85
###begin title 86
Authors' contributions
###end title 86
###begin p 87
KE wrote the article and performed the statistical analyses with the assistance of KH and YL. LUR and SW organized data and sample collection. CB oversaw the genotyping procedures and KE assisted on the genotyping. KE and YL selected the polymorphisms. SW and JL co-ordinated the study. KH, JP, KSC, ETL, PH, JL and SW contributed to the conception and design of the project and crucially revised the manuscript. All authors read and approved the final manuscript.
###end p 87
###begin title 88
Supplementary Material
###end title 88
###begin title 89
Additional file 1
###end title 89
###begin p 90
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 198 204 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 293 296 293 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 401 405 401 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Microsoft Word document containing supplementary figures 1 and 2, and supplementary tables 1 to 7. These detail the statistics for the genotyping results, successfully genotyped SNPs in the ATM and ERBB2 genes, risk of breast cancer associated with the ATM and ERBB2 genes, association of the ATM, CHEK2 and ERBB2 genes with the risk of tumour-characteristic-defined breast cancer and LD plots of the ATM and ERBB2 genes.
###end p 90
###begin p 91
Click here for file
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
###xml 485 490 <span type="species:ncbi:9606">women</span>
###xml 670 682 <span type="species:ncbi:9606">participants</span>
We are indebted to Christer Hallden at Swegene laboratories, Malmo, Sweden, for overseeing the isolation of DNA from the blood samples, Meah Wee Yang and Ong Eng Hu Jason for genotyping, Lim Siew Lan and Irene Chen for isolating DNA from paraffin-embedded tissue, Marie Vivian Wong Tzu Yen for retrieving the SNP information, Frans Verhoeff for processing the genotyping data, and Mattias Hammarstrom and Eija Flygare for reviewing the medical records. We are also grateful to all the women who took the time and effort to participate in this study and Anna Christensson and Boel Bissmarck, who obtained consent and co-ordinated the collecting of samples from the study participants. The Wallenberg Consortium North and the Swedish Foundation for Strategic Research also deserve our gratitude for financially supporting KH. This study was supported by funding from the Agency for Science and Technology and Research of Singapore (A*STAR), Susan G Komen Breast Cancer Foundation and National Institute of Health (grant number, R01 CA 104021).
###end p 93
###begin article-title 94
The genetic epidemiology of breast cancer genes
###end article-title 94
###begin article-title 95
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
###end article-title 95
###begin article-title 96
Genetic background is an important determinant of metastatic potential
###end article-title 96
###begin article-title 97
###xml 72 76 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 82 97 <span type="species:ncbi:10090">transgenic mice</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease
###end article-title 97
###begin article-title 98
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers
###end article-title 98
###begin article-title 99
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
###end article-title 99
###begin article-title 100
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
###end article-title 100
###begin article-title 101
Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1
###end article-title 101
###begin article-title 102
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
###end article-title 102
###begin article-title 103
A single ataxia telangiectasia gene with a product similar to PI-3 kinase
###end article-title 103
###begin article-title 104
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks
###end article-title 104
###begin article-title 105
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
###end article-title 105
###begin article-title 106
###xml 10 18 <span type="species:ncbi:9606">patients</span>
Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries
###end article-title 106
###begin article-title 107
Incidence of cancer in 161 families affected by ataxia-telangiectasia
###end article-title 107
###begin article-title 108
Cancer risks and mortality in heterozygous ATM mutation carriers
###end article-title 108
###begin article-title 109
Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia
###end article-title 109
###begin article-title 110
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
###end article-title 110
###begin article-title 111
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies
###end article-title 111
###begin article-title 112
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
###end article-title 112
###begin article-title 113
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
###end article-title 113
###begin article-title 114
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
###end article-title 114
###begin article-title 115
###xml 50 55 <span type="species:ncbi:9606">human</span>
Amplification of a novel v-erbB-related gene in a human mammary carcinoma
###end article-title 115
###begin article-title 116
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
###end article-title 116
###begin article-title 117
The neu oncogene encodes an epidermal growth factor receptor-related protein
###end article-title 117
###begin article-title 118
###xml 19 24 <span type="species:ncbi:9606">human</span>
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity
###end article-title 118
###begin article-title 119
Untangling the ErbB signalling network
###end article-title 119
###begin article-title 120
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype
###end article-title 120
###begin article-title 121
Requirement for neuregulin receptor erbB2 in neural and cardiac development
###end article-title 121
###begin article-title 122
###xml 18 23 <span type="species:ncbi:9606">human</span>
ERBB2 oncogene in human breast cancer and its clinical significance
###end article-title 122
###begin article-title 123
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
###end article-title 123
###begin article-title 124
###xml 43 48 <span type="species:ncbi:9606">human</span>
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
###end article-title 124
###begin article-title 125
UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1
###end article-title 125
###begin article-title 126
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice
###end article-title 126
###begin article-title 127
###xml 123 128 <span type="species:ncbi:9606">human</span>
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
###end article-title 127
###begin article-title 128
A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea
###end article-title 128
###begin article-title 129
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
###end article-title 129
###begin article-title 130
Association of family history and other risk factors with breast cancer risk (Sweden)
###end article-title 130
###begin article-title 131
###xml 101 106 <span type="species:ncbi:9606">women</span>
The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years
###end article-title 131
###begin article-title 132
Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden)
###end article-title 132
###begin article-title 133
Brassica vegetables and breast cancer risk
###end article-title 133
###begin article-title 134
Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples
###end article-title 134
###begin article-title 135
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 135
###begin article-title 136
Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms
###end article-title 136
###begin article-title 137
Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study
###end article-title 137
###begin article-title 138
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 138
###begin article-title 139
Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping
###end article-title 139
###begin article-title 140
Obtaining unbiased estimates of tagging SNP performance
###end article-title 140
###begin article-title 141
Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee
###end article-title 141
###begin article-title 142
Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer
###end article-title 142
###begin article-title 143
Score tests for association between traits and haplotypes when linkage phase is ambiguous
###end article-title 143
###begin article-title 144
Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power
###end article-title 144
###begin article-title 145
Sample size requirements for matched case-control studies of gene-environment interaction
###end article-title 145
###begin article-title 146
Genes, environment and the value of prospective cohort studies
###end article-title 146
###begin article-title 147
Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology
###end article-title 147
###begin article-title 148
Linkage Disequilibrium Mapping of CHEK2: Common Variation and Breast Cancer Risk
###end article-title 148
###begin article-title 149
###xml 26 32 <span type="species:ncbi:9606">humans</span>
Linkage disequilibrium in humans: models and data
###end article-title 149
###begin article-title 150
An utter refutation of the 'Fundamental Theorem of the HapMap'
###end article-title 150
###begin article-title 151
Effect of germ-line genetic variation on breast cancer survival in a population-based study
###end article-title 151
###begin article-title 152
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients
###end article-title 152
###begin article-title 153
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant
###end article-title 153
###begin article-title 154
Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk
###end article-title 154
###begin article-title 155
Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study
###end article-title 155
###begin article-title 156
Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study
###end article-title 156
###begin article-title 157
The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk
###end article-title 157
###begin article-title 158
HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses
###end article-title 158
###begin article-title 159
###xml 58 63 <span type="species:ncbi:9606">women</span>
ATM haplotypes and breast cancer risk in Jewish high-risk women
###end article-title 159
###begin article-title 160
ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity
###end article-title 160
###begin article-title 161
Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk
###end article-title 161
###begin article-title 162
The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort
###end article-title 162
###begin article-title 163
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients
###end article-title 163
###begin article-title 164
The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer
###end article-title 164
###begin article-title 165
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer
###end article-title 165
###begin article-title 166
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history
###end article-title 166
###begin article-title 167
###xml 39 47 <span type="species:ncbi:9606">patients</span>
ATM missense mutations are frequent in patients with breast cancer
###end article-title 167
###begin article-title 168
Heterozygous ATM mutations do not contribute to early onset of breast cancer
###end article-title 168
###begin article-title 169
The role of ataxia-telangiectasia heterozygotes in familial breast cancer
###end article-title 169
###begin article-title 170
ATM heterozygosity and cancer risk
###end article-title 170
###begin article-title 171
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
###end article-title 171
###begin article-title 172
Dominant negative ATM mutations in breast cancer families
###end article-title 172
###begin article-title 173
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
###end article-title 173
###begin article-title 174
An allelic variant at the ATM locus is implicated in breast cancer susceptibility
###end article-title 174
###begin article-title 175
Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
###end article-title 175
###begin article-title 176
###xml 86 94 <span type="species:ncbi:9606">patients</span>
A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls
###end article-title 176
###begin title 177
Figures and Tables
###end title 177
###begin p 178
Characteristics of the breast cancer cases in the parent study and the present genetic study
###end p 178
###begin p 179
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aFrom the date of diagnosis until 31 December 2003.
###end p 179
###begin p 180
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 154 160 <span type="species:ncbi:9606">person</span>
bFrom the date of diagnosis until 31 December 2003 or until the date of death or emigration, whichever came first. Calculated as breast cancer deaths per person-year of follow-up.
###end p 180
###begin p 181
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cChi-squared test of independence between the parent and the present studies.
###end p 181
###begin p 182
ER, oestrogen receptor; PR, progesterone receptor
###end p 182
###begin p 183
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
Characteristics of the ATM, CHEK2 and ERBB2 tagSNPs and their association with breast cancer survival
###end p 183
###begin p 184
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aIn controls.
###end p 184
###begin p 185
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 7 12 <span type="species:ncbi:9606">women</span>
bAmong women with breast cancer.
###end p 185
###begin p 186
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cHRs are assessed assuming co-dominance and show the increase/decrease in risk of death from breast cancer with each addition of the minor allele compared with homozygotes of the major allele.
###end p 186
###begin p 187
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
dNot genotyped in the patients who participated through tissue sample donation.
###end p 187
###begin p 188
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
eAlso named I655V.
###end p 188
###begin p 189
ATM, ataxia-telangiectasia mutated; CHEK2, checkpoint kinase 2; CI, confidence interval; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; HR, hazard ratio; SNP, single nucleotide polymorphism; tagSNP, haplotype-tagging SNP.
###end p 189
###begin p 190
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
tagSNP haplotypes in the ATM, CHEK2 and ERBB2 genes in relation to breast cancer survival
###end p 190
###begin p 191
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aInformation on at least one tagSNP.
###end p 191
###begin p 192
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
b11 rare haplotypes combined. Each haplotype has frequency <3% among the controls.
###end p 192
###begin p 193
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cProbability ratio test.
###end p 193
###begin p 194
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
d19 rare haplotypes combined. Each haplotype has frequency <3% among the controls.
###end p 194
###begin p 195
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
e19 rare haplotypes combined. Each haplotype has frequency <3% among the controls.
###end p 195
###begin p 196
ATM, ataxia-telangiectasia mutated; CHEK2, checkpoint kinase 2; CI, confidence interval; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; HR, hazard ratio; tagSNP, haplotype-tagging SNP.
###end p 196

